磷酸二酯酶-4D抑制剂治疗成人脆性X综合征的随机安慰剂对照2期临床试验
本研究为24周随机、安慰剂对照、双向交叉2期试验,纳入30例18-41岁男性脆性X综合征患者,口服BPN14770 25 mg每日两次或安慰剂。主要结局为安全性和耐受性,BPN14770耐受良好且两组无显著差异。关键次要疗效指标显示认知和日常功能改善,语言相关认知域及照料者评定的语言和日常功能均有显著获益。
要点
- BPN14770 25 mg每日两次在成人男性脆性X综合征患者中耐受良好。
- 认知获益见于NIH Toolbox口语阅读识别、图片词汇和认知晶体复合评分。
- 照料者视觉模拟评分显示语言和日常功能有临床意义的改善。
核心结论
- BPN14770在成人男性脆性X综合征患者中耐受良好,并改善语言相关认知和日常功能。
研究设计与样本
- 24周随机、安慰剂对照、双向交叉2期试验,纳入30例18-41岁男性脆性X综合征患者。
- 参与者口服BPN14770 25 mg每日两次或安慰剂。
- 主要结局为安全性和耐受性,次要疗效结局包括认知表现、照料者评定量表和医生评定量表。
主要发现
- BPN14770耐受良好,活性药物与安慰剂组间无有意义差异。
- NIH Toolbox认知电池显示口语阅读识别最小二乘均值差异+2.81(P=0.0157)。
- 图片词汇最小二乘均值差异+5.81(P=0.0342),认知晶体复合评分+5.31(P=0.0018)。
- 照料者视觉模拟评分显示语言改善+14.04(P=0.0051),日常功能改善+14.53(P=0.0017)。
关键数值与推荐
- BPN14770 25 mg每日两次口服,疗程24周。
- 认知获益判定基于NIH Toolbox认知电池评估。
- 照料者评定语言和日常功能获益达临床意义。
临床怎么用
- 对于成人男性脆性X综合征患者,BPN14770可能改善语言相关认知和日常功能。
- 治疗耐受性良好,未观察到与安慰剂组的有意义差异。
局限性
- 样本量较小(30例),仅纳入成人男性患者,结果外推需谨慎。
- 研究为2期试验,需更大规模试验验证疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients with fragile X syndrome (FXS). This phase 2 trial was a 24-week randomized, placebo-controlled, two-way crossover study in 30 adult male patients (age 18-41 years) with FXS. Participants received oral doses of BPN14770 25 mg twice daily or placebo. Primary outcomes were prespecified as safety and tolerability with secondary efficacy outcomes of cognitive performance, caregiver rating scales and physician rating scales (ClinicalTrials.gov identifier: NCT03569631 ). The study met the primary outcome measure since BPN14770 was well tolerated with no meaningful differences between the active and placebo treatment arms. The study also met key secondary efficacy measures of cognition and daily function. Cognitive benefit was demonstrated using the National Institutes of Health Toolbox Cognition Battery assessments of Oral Reading Recognition (least squares mean difference +2.81, P = 0.0157), Picture Vocabulary (+5.81, P = 0.0342) and Cognition Crystallized Composite score (+5.31, P = 0.0018). Benefit as assessed by visual analog caregiver rating scales was judged to be clinically meaningful for language (+14.04, P = 0.0051) and daily functioning (+14.53, P = 0.0017). Results from this study using direct, computer-based assessment of cognitive performance by adult males with FXS indicate significant cognitive improvement in domains related to language with corresponding improvement in caregiver scales rating language and daily functioning.
引用
- Berry-Kravis EM, Harnett MD, Reines SA, et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat Med. 2021. PMID: 33927413. doi:10.1038/s41591-021-01321-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。